ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 1842

Social Vulnerability Index, Type 2 Lupus Symptoms, and Select Dysregulated Immune Features Identify Stage 2 (Pre-classification) SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort

(1830–1854) Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2198

Sociocultural Influences on Pregnancy Planning for Individuals Diagnosed with SLE in an Urban Hispanic Population: A Qualitative Study with Considerations for a Holistic Approach

(2195–2226) Reproductive Issues in Rheumatic Disorders Posters

10:30AM-12:30PM: Abstract Number: 2312

Sociodemographic Characteristics and Healthcare Utilization in Patients with IBD-Associated Arthritis vs. IBD Alone: A Nationwide Inpatient Analysis

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1785

Soluble CD14 Amplifies Chondrocyte Inflammatory Responses to Lipopolysaccharide and Is Targetable by Anti-CD14 Therapy

(1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2450

Spanish Real-World Ambispective Multicenter Registry of Anifrolumab in Systemic Lupus Erythematosus: Efficacy and Safety at 3- and 6-Month Follow-Up (ANIFRO-Reu Study)

(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1789

Spatial Analysis of Advanced Osteoarthritis Synovial Tissue

(1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 1787

Spatial and Quantitative Semiautomated Image Analysis of Synovial Biopsies Studied Using a Novel High-Plex Immunofluorescence Platform

(1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2233

Spatial Multi-omics Demonstrates Shared Immune States Across Autoimmune Diseases and Target Tissues in the Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases Network (AMP AIM)

(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1856

Spatial Proteomic-based Phenotyping of Fibroblast Populations and their Microenvironment in Systemic Sclerosis Primary Heart Involvement

(1855–1876) Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: Abstract Number: 1819

Spatial Transcriptomic Profiling Reveals Interferon Activation and CD8⁺ T Cell Dominance in Systemic Juvenile Idiopathic Arthritis-Macrophage Activation Syndrome Liver Inflammation

(1809–1829) Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 1847

Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury

(1830–1854) Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 1933

Specialist Wound Care Services Provision and Sharp Debridement Practices for Digital Ulcers (DU) Management in Systemic Sclerosis (SSc): An International Survey

(1914–1935) Health Services Research Poster III

10:30AM-12:30PM: Abstract Number: 1781

Specific gut microbiome remodeling occurs after induction of OA via DMM surgery compared to sham surgery

(1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2434

Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2025

Spectrum of Autoantibodies in CNS Demyelinating Diseases: Clinical, Laboratory and Imaging Associations

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].